[Skip to Content]
[Skip to Content Landing]
February 1, 1985

Lipid Research Clinics Coronary Primary Prevention Trial Results

Author Affiliations

Psychiatric Clinic Helsinki University Central Hospital

JAMA. 1985;253(5):635-636. doi:10.1001/jama.1985.03350290037018

To the Editor.—  I refer to the article entitled "The Lipid Research Clinics Coronary Primary Prevention Trial Results,"1 a multicenter, randomized, double-blind study that tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia. This study found that those who had received cholestyramine resin experienced reductions in average total plasma and low-density lipoprotein cholesterol, a 24% reduction in definite CHD death, and a 19% reduction in nonfatal myocardial infarction. However, the risk of death from all causes in 7.4 years was not significantly reduced in the cholestyramine group. The reason was that there was a greater number of violent and accidental deaths in the cholestyramine group.The authors say that since no plausible connection could be established between cholestyramine treatment and violent or accidental death, it is difficult to conclude that this could be anything but a